Short communication: A single step assay for rapid evaluation of inhibitors targeting HIV type 1 tat-mediated long terminal repeat transactivation

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 902-906

  Chande, Ajit G ^a   Baba, Masanori ^b   Mukhopadhyaya, Robin ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

K 37; LENTIVIRUS VECTOR; LUCIFERASE; QUINOLONE DERIVATIVE; SHORT HAIRPIN RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME INHIBITION; GENE CASSETTE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSACTIVATION;

CELLS, CULTURED; GENE EXPRESSION REGULATION, VIRAL; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LUCIFERASES; REGULATORY SEQUENCES, NUCLEIC ACID; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION;

EID: 84864212880     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0228     Document Type: Article

References (31)

1. Berkhout B, Silverman R, and Jeang K: Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989;59:273-282.
2. Feinberg M, Baltimore D, and Frankel A: The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 1991;88:4045-4049.
3. Harrich D, Ulich C, Garcia-Martinez L, et al.: Tat is required for efficient HIV-1 reverse transcription. EMBO J 1997;16: 1224-1235.
4. Myers G, Korber B, and Foley B: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM,1998; pp. III-11 to III-26.
5. Dingwall C, Ernberg I, Gait MJ, et al.: Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989;86:6925-6929.
6. Mavankal G, Ignatius Ou SH, Oliver H, et al.: Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc Natl Acad Sci USA 1996;93:2089-2094.
7. Davidson A, Leeper T, Athanassiou Z, et al.: Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci USA 2009;106:11931-11936.
8. He N, Liu M, Hsu J, et al.: HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell 2010;38:428-438.
9. Sobhian B, Laguette N, Yatim A, et al.: HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 2010;38:439-451.
10. He N and Zhou Q: New insights into the control of HIV-1 transcription: When tat meets the 7SK snRNP and super elongation complex (SEC). J Neuroimmune Pharmacol 2011;6:260-268.
11. Hsu M, Schutt A, Holly M, et al.: Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 1991;254:1799-1802.
12. Gatignol A and Jeang K: Tat as a transcriptional activator and a potential therapeutic target for HIV-1. Adv Pharmacol 2000;48:209-227.
13. Baba M: Recent status of HIV-1 gene expression inhibitors. Antiviral Res 2006;71:301-306.
14. Richter S, Parolin C, Gatto B, et al.: Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother 2004;48:1895-1899.
15. Koseki S, Ohkawa J, Yamamoto R, et al.: A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase. J Control Release 1998;53:159-173.
16. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, et al.: Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol 2000;74:3740-3751.
17. Corish P and Tyler-Smith C: Attenuation of green fluorescent protein half-life in mammalian cells. Prot Engineer 1999;12:1035-1040.
18. Ravi D and Mitra D: HIV-1 long terminal repeat promoter regulated dual reporter: Potential use in screening of transcription modulators. Anal Biochem 2007;360:315-317.
19. Ranga U, Shankarappa R, Siddappa N, et al.: Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 2004;78:2586-2590.
20. Pei Y and Tuschl T: On the art of identifying effective and specific siRNAs. Nature Methods 2006;3:670-676.
21. Hauber J, Perkins A, Heimer EP, et al.: Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc Natl Acad Sci USA 1987;84:6364-6368.
22. Santhosh C, Tamhane MC, Kamat RH, et al.: A lentiviral vector with novel multiple cloning sites: Stable transgene expression in vitro and in vivo. Biochem Biophys Res Commun 2008;371:546-550.
23. Baba M, Okamoto M, Kawamura M, et al.: Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 1998;53:1097-1103.
24. Okamoto H, Cujec T, Okamoto M, et al.: Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 2000;272:402-408.
25. Alam J and Cook JL: Reporter genes: Application to the study of mammalian gene transcription. Anal Biochem 1990;188:245-254.
26. Daelemans D, De Clercq E, and Vandamme A: A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. J Virol Methods 2001;96:183-188.
27. Emmanuel A, Christine T, James M, et al.: Nuclear factor 90 (NF90) targeted to TAR RNA inhibits transcriptional activation of HIV-1. Retrovirology 2007;4:41-44.
28. Jiang M, Lin J, and Chen S: Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun 1996;226:1-7.
29. Lisziewicz J, Sun D, Smythe J, et al.: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993;90:8000-8004.
30. Yang M: Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr Drug Targets Infect Disorders 2005;5:433-444.
31. Kira T, Merin J, Baba M, et al.: Anti-Tat MTT assay: A novel anti-HIV drug screening system using the viral regulatory network of replication. AIDS Res Hum Retroviruses 1995;11:1359-1366.